Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma

1. Background Lung cancer remains the leading cause of oncological mortality worldwide, representing a formidable challenge to global public health systems (1,2). Within the broad classification of lung malignancies, non-small cell lung cancer (NSCLC) accounts for the vast majority of cases, with lung adenocarcinoma (LUAD) being the most frequent histological subtype diagnosed in clinical practice. The molecular characterization of LUAD has fundamentally changed the therapeutic approach, shifting the focus from broad cytotoxic treatments to personalized medicine based on specific genomic alterations. Among these, mutations in the epidermal growth factor receptor (EGFR) gene stand out as one of the most significant and actionable therapeutic targets (3,4). The prevalence of EGFR mutations exhibits a striking geographic and ethnic disparity; while occurring in approximately 10-15% of Western populations, these mutations are found in nearly 50% of Asian patients with LUAD (5). This high frequency in the Asian population necessitates a specialized focus on optimizing treatment strategies for this demographic. Historically, the identification of these mutations served as the catalyst for the development of targeted therapies that have significantly improved survival outcomes. Despite these advancements, lung cancer continues to impose a heavy burden due to its aggressive nature and the eventual development of resistance to current therapies. Understanding the specific genomic landscape of LUAD in the Asian context is not merely an academic exercise but a clinical necessity to improve the prognosis of millions of patients. As we look toward the future of oncology, refining our approach to EGFR-mutant disease remains a top priority to further reduce the mortality rates associated with this devastating illness.

The treatment of EGFR-mutant LUAD has undergone a remarkable transformation since the discovery of sensitizing mutations in 2004 (6). The introduction of first-generation EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, established a new paradigm by demonstrating superior efficacy and better tolerability compared to platinum-based chemotherapy in the first-line setting. These agents work by reversibly binding to the ATP-binding pocket of the EGFR kinase domain, thereby inhibiting downstream signaling pathways that drive tumor cell proliferation. However, most patients eventually experience disease progression, often due to the acquisition of the T790M resistance mutation (7). Second-generation TKIs, including afatinib and dacomitinib, were developed as irreversible inhibitors designed to provide more potent blockade of the ErbB family; while effective, their clinical utility was frequently limited by dose-related toxicities such as diarrhea and skin rash. The third-generation TKI, osimertinib, represented a major breakthrough by selectively targeting both sensitizing mutations and the T790M resistance mutation while sparing wild-type EGFR (8). The FLAURA trial demonstrated that osimertinib significantly extended progression-free survival and overall survival compared to first-generation agents (9), establishing it as the preferred first-line standard of care for treatment-naïve advanced LUAD. Nowadays, there are several third-generation EGFR-TKIs, including agents such as osimertinib, lazertinib, aumolertinib, and furmonertinib (10). While the clinical response to these agents is initially robust, the inevitable development of resistance and the heterogeneity of patient outcomes indicate that there is significant room for therapeutic optimization. To address these limitations, recent research has focused on intensifying frontline treatment through combination strategies. One major approach involves the addition of platinum-based chemotherapy to third-generation TKIs, a strategy validated by the FLAURA2 trial (11), which demonstrated a significant extension in progression-free survival compared to TKI monotherapy. Another evolving paradigm is the use of bispecific antibodies, such as amivantamab, which targets both EGFR and MET pathways. The MARIPOSA study highlighted the potential of combining amivantamab with lazertinib to provide a more comprehensive blockade of oncogenic signaling, thereby delaying the onset of resistance (12). These advancements suggest that while monotherapy remains a potent tool, the future of EGFR-mutant LUAD management lies in identifying the most effective combination regimens to further prolong patient survival.

Aumolertinib is an orally administered, irreversible third-generation EGFR-TKI specifically engineered to address the limitations of earlier-generation therapies. Developed with a focus on high selectivity, the drug targets common sensitizing mutations, such as exon 19 deletions and the L858R point mutation, as well as the resistance mutation. A defining pharmacological feature of aumolertinib is its ability to irreversibly bind to the kinase domain while sparing the wild-type form of the receptor. This selectivity is critical for clinical practice, as it significantly reduces the incidence of off-target toxicities-such as severe skin rash and diarrhea-that frequently led to dose interruptions or discontinuations with first- and second-generation inhibitors (13). The clinical efficacy of aumolertinib was established through the pivotal phase 3 AENEAS trial (14). In this study, treatment-naïve patients receiving aumolertinib achieved a median progression-free survival of 19.3 months, a result that was not only significantly superior to the 9.9 months observed with gefitinib but also remarkably consistent with the outcomes of other leading third-generation TKIs like osimertinib. Beyond systemic control, aumolertinib and its active N-desmethyl metabolite, HAS-719, demonstrate potent blood-brain barrier penetration (13). This characteristic is vital for the management of NSCLC, where central nervous system (CNS) metastases represent a major cause of morbidity and treatment failure. Clinical data from both the AENEAS and APOLLO trials (14,15) confirmed that aumolertinib provides robust intracranial activity, with objective response rates and progression-free survival in patients with brain metastases comparable to those in the overall study populations.

Aumolertinib also presents a unique safety profile. While it shares some class-wide side effects, such as a manageable risk of QT interval prolongation and rare instances of interstitial lung disease, it is frequently associated with elevations in blood creatinine phosphokinase. In the AENEAS trial, increased CPK was the most frequent grade ≥ 3 adverse event in the aumolertinib arm. However, these elevations are typically asymptomatic and rarely lead to permanent treatment discontinuation. Importantly, the incidence of rash and diarrhea was lower with aumolertinib than with gefitinib, reflecting its superior selectivity over wild-type.

Expanding its clinical utility, recent phase II evidence has investigated the role of aumolertinib as a backbone for combination therapy. In a study evaluating first-line aumolertinib plus pemetrexed and carboplatin, the combination achieved a striking objective response rate (ORR) of 91.2% and a median progression-free survival of 28.0 months (16). This intensified approach did not yield new safety signals, and the toxicity profile remained consistent with the established side effects of the individual agents. The most common high-grade adverse events in the combination setting were hematological, such as decreased neutrophil counts, which are primarily attributed to the chemotherapy component. Furthermore, exploratory analyses in these trials highlighted the prognostic value of circulating tumor DNA (ctDNA) clearance, where patients achieving molecular clearance within the first few cycles of treatment experienced significantly prolonged progression-free survival compared to those who did not. These findings underscore the potential of aumolertinib not only as a potent monotherapy but as a safe and effective foundation for precision-based combination strategies aimed at maximizing the depth of response in EGFR-mutant NSCLC.

While EGFR mutations are collectively recognized as primary oncogenic drivers in lung adenocarcinoma, it is increasingly evident that these genomic alterations are not created equal. The two most prevalent variants, exon 19 deletions (Ex19del) and the L858R point mutation in exon 21, account for approximately 90% of all sensitizing EGFR mutations. Despite their shared classification, these variants exhibit distinct biochemical properties and clinical behaviors. Specifically, the L858R mutation has been consistently associated with poorer treatment outcomes compared to Ex19del across multiple generations of tyrosine kinase inhibitors. Structural analyses reveal that the L858R substitution leads to a less stable active conformation of the kinase domain (17), resulting in a lower binding affinity for TKIs than that observed with Ex19del. This reduced sensitivity manifests clinically as shorter progression-free survival and lower response rates when these patients are treated with TKI monotherapy.

Furthermore, the L858R subgroup appears to harbor greater genomic instability and a higher frequency of co-occurring mutations, such as TP53 alterations, which further compromise the efficacy of targeted agents (18). To mitigate this inferior prognosis, intensified treatment strategies have been explored. Emerging evidence from large-scale clinical trials and smaller phase II studies indicates that the addition of chemotherapy may be particularly beneficial for this "high-risk" subgroup. Interestingly, recent data suggest that combination therapy can potentially close the gap in efficacy, improving the survival outcomes of L858R patients to a level comparable to those historically seen in Ex19del patients. These observations emphasize the necessity of moving beyond a "one-size-fits-all" approach and developing more aggressive, tailored regimens for patients harboring the L858R mutation to overcome their inherent resistance and achieve deeper clinical responses.

While intensifying first-line treatment through combination therapy appears to be a feasible approach for improving outcomes in EGFR-mutated disease, it introduces significant clinical and economic challenges that cannot be ignored. Evidence from large-scale trials indicates that the survival benefits of adding chemotherapy to third-generation TKIs are not distributed equally across the entire patient population. In fact, data from the FLAURA2 study showed that while the combination improved progression-free survival, a substantial proportion of patients in the monotherapy arm remained progression-free at 24 months (41% vs. 57% in the combination arm), suggesting that roughly 16% of the population drives the incremental benefit (11). Despite this disproportionate gain, the entire cohort is exposed to the increased toxicity inherent in cytotoxic regimens. In fact, \~40% of the population will simply suffer from the toxicities without obtaining any benefit. Common high-grade adverse events, particularly hematological toxicities such as neutropenia and anemia, as well as gastrointestinal intolerance and peripheral neuropathy, are significantly more frequent in combination arms than in monotherapy groups. For instance, earlier trials observed that the rate of grade 3 or 4 drug-related adverse events more than doubled with the addition of chemotherapy (42% vs. 19%), leading to a higher rate of dose interruptions and a potential reduction in overall quality of life (19). In fact, in FLUAR2 trial, for example, the median treatment duration of chemotherapy and osimertinib in the combination arm were 8.3 months and 30.5 months, respectively, suggesting that many patients could not tolerate the chemotherapy side effect and withdrew from the chemotherap